Today: 19 May 2026
IBM stock hit by worst drop since 2000 after Anthropic’s COBOL claim — what to watch next
24 February 2026
2 mins read

IBM stock hit by worst drop since 2000 after Anthropic’s COBOL claim — what to watch next

New York, Feb 24, 2026, 04:59 EST — Premarket

  • IBM tumbled 13.2% by the close on Monday, marking its sharpest single-day drop since October 18, 2000.
  • Shares declined after Anthropic said its Claude Code tool could accelerate COBOL modernization.
  • IBM’s upcoming remarks at a March 3 conference are in focus for investors, coming just ahead of the company’s April 22 earnings.

IBM shares took a beating Monday, plunging 13.2% to $223.35—their sharpest single-day fall since the late ’90s—after Anthropic claimed its AI tools could overhaul COBOL systems still running on Big Blue’s mainframes. That news also stung other software players. CrowdStrike and Datadog both lost ground as traders started questioning how disruptive the fresh wave of AI products could be across the sector.

The selloff got investors’ attention, zeroing in on a question that’s been hanging over the market for months: will “AI for code” mean big services names just cut costs, or could it actually open up a new round of products to push? IBM, for its part, keeps emphasizing its role as the go-to for major enterprises trying to keep essential systems up and running during upgrades.

COBOL — short for Common Business-Oriented Language — remains entrenched in banks, insurers, government agencies. Its persistence has long shored up IBM’s mainframe business, consistently generating modernization projects.

Anthropic says the economics are changing. According to the company, Claude Code now handles the initial analysis that once consumed the bulk of time on COBOL modernization—think dependency mapping and flagging migration risks. Teams, the company claims, can finish these projects “in quarters instead of years.” Claude

IBM fired back that day, calling the discussion a category mistake. “Translating code is one thing. Modernizing a platform is something else entirely,” said Rob Thomas, IBM’s senior vice president for software and chief commercial officer. He pointed to the true challenge: handling everything around the code—data, transactions, security, and operations. Syntax isn’t the main issue. IBM Newsroom

Even so, Monday’s action made clear the market doesn’t hesitate to hit anything endangering the modernization business model. The selloff served as a wake-up: the ranks of “AI winners” can shuffle in a flash, no matter how long a company has been in enterprise automation.

Evercore ISI’s Amit Daryanani pointed out that while easier migration could initially appear like a downside, customers have already had options for years. Many continue to stick with IBM’s platforms—reliability and regulatory needs play a role, he told Moneycontrol, which cited Bloomberg.

The risk is clear enough: should clients start thinking AI tools handle more of the modernization work solo, IBM’s grip on services pricing could loosen, and fresh competitors might pick up some of that business. That scenario would hit just as firms are still squeezing IT budgets even as they pour money into AI.

The bull argument isn’t neat, but it’s there: if modernization tools accelerate, project numbers might jump, and regulated clients could stick with IBM systems, even if AI takes the sting out of switching. The key issue—who grabs the wallet share as these tools advance—remains.

This week, attention turns to IBM’s remarks at the Morgan Stanley Technology, Media and Telecom Conference on March 3. After that, the spotlight shifts to IBM’s preliminary first-quarter earnings, set for April 22, as investors scan for cues on demand and any forward-looking statements.

Stock Market Today

  • Asian Shares Mixed; Kospi Drops 3% Amid Volatile Oil Prices
    May 19, 2026, 4:28 AM EDT. Asian stock markets showed mixed performances on Tuesday, with South Korea's Kospi index tumbling 3%. The sell-off was driven by ongoing volatility in oil prices, which continue to sway investor sentiment. Analysts noted that fluctuations in crude oil markets are impacting broader market stability, contributing to cautious trading across Asia. The Kospi's decline reflects concerns over energy costs and their potential impact on corporate earnings and economic growth in the region. Meanwhile, other Asian markets saw varied movements as investors balanced risks amid uncertain commodity trends.

Latest articles

T1 Energy Stock Just Popped 23%. The Filing Behind the Move Is the Story

T1 Energy Stock Just Popped 23%. The Filing Behind the Move Is the Story

19 May 2026
T1 Energy Inc. shares surged 23.46% to $7.00 Monday after a regulatory filing revealed Situational Awareness LP held 10 million shares, valued at $43.9 million as of March 31. Trading volume hit 88 million shares, far above the 20-day average. T1 reported Q1 net sales of $177.6 million and a net loss to common stockholders of $21.4 million. Construction at its G2_Austin solar site remains on schedule.
HIVE Stock Up 29% While Nasdaq Moves Lower as Traders Eye AI Gigafactory

HIVE Stock Up 29% While Nasdaq Moves Lower as Traders Eye AI Gigafactory

19 May 2026
HIVE Digital Technologies closed at $3.46 on Nasdaq Monday, up 28.6%, and rose to $3.59 after hours following news of a planned 320 MW AI data center near Toronto targeting over 100,000 GPUs. The project is expected to cost C$3.5 billion and open in late 2027. Shares of other crypto miners fell as bitcoin traded near $77,142.
Ameren Holders Approve CEO Compensation, $14 Million Package Not Unanimous

Ameren Holders Approve CEO Compensation, $14 Million Package Not Unanimous

19 May 2026
Ameren shareholders approved executive pay, re-elected the full board, and ratified PwC as auditor. CEO Martin J. Lyons, Jr.’s 2025 compensation rose to $14.06 million, up from $9.73 million the previous year. The “say-on-pay” proposal received over 208 million votes in favor. Ameren shares last traded at $107.38, up $1.02.

Popular

Sunshine Biopharma Shares Volatile After $6M Deal, 50-Cent Mark in Focus

Sunshine Biopharma Shares Volatile After $6M Deal, 50-Cent Mark in Focus

19 May 2026
Sunshine Biopharma shares surged as much as 516% before settling up 78% at $0.51 in heavy after-hours Nasdaq trading Monday, following a $6 million public offering priced at $0.50 per unit. More than 436 million shares changed hands, far exceeding the company’s 5 million shares outstanding. The deal includes 12 million units with warrants, raising dilution concerns. Closing is expected around May 19.
Haleon PLC share price slips ahead of FY 2025 results as investors eye guidance
Previous Story

Haleon PLC share price slips ahead of FY 2025 results as investors eye guidance

American Express stock tumbles 7% as “AI scare trade” hits payments; what to watch before the open
Next Story

American Express stock tumbles 7% as “AI scare trade” hits payments; what to watch before the open

Go toTop